Abstract 1980
Background
Necrotizing fasciitis (NF) is a live-treating acute skin infection of soft tissues and muscles, extended from a trivial skin lesion, with rapid progression to necrosis. It is relatively uncommon and has a high mortality rate (∼32.2%) approaching 100% without treatment. Most cases present an anaerobic bacterium that produce gas, accumulated in the soft tissue spaces giving the characteristic image of gas gangrene on X rays (1). Site inspection reveals inflammation, oedema, and discoloration or gangrene and anaesthesia. A distinguishing clinical feature is the induration of the subcutaneous tissues (2). Early diagnosis is mandatory. Delay is associated with more extensive surgery and higher rates of amputation and mortality (1). Therapy includes radical surgical debridement with empirical broad-spectrum antibiotic coverage (2,3). Immunosuppressed patients or suffering from haematological malignancies are particularly at risk presenting an atypical etiopathology (3).
Methods
Two cases were retrospectively reviewed through medical history records to determine possible nursing implications to prevent or detect earlier cases in the future.
Results
Patient A: 53 year old woman being treated for Acute Myeloid Leukaemia (AML) with grade 4 neutropenia. She referred pain in her catheter site and presented fever and hypotension. After some days NF was diagnosed requiring 3 surgical interventions. Pseudomonas Aeruginosa was isolated in blood cultures. Patient B: 71 year old woman under treatment for AML with grade 3 neutropenia. NF in her Peripheral Insertion Central Catheter site was diagnosed. She presented no symthoms the days before but fever in the diagnosis. She required 2 surgical interventions. Klebsiella oxytoca and Enterobacter cloacae were isolated in blood cultures. Intensive care admission and longer hospitalization was required in both cases. NF was controlled but they had long term consequences (loss of mobility, paresthesia or pain).
Conclusions
FN is a rare potentially lethal infection in neutropenic patients. Oncology Nurses must be aware of this complication and patient implications in order to detect it earlier. Prompt diagnosis is crucial to prevent major surgical trauma, mortality and long-term morbidity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hosptial Clínic de Barcelona.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract